What are the organ at risk (OAR) tolerances for the medulla oblongata in Stereotactic Body Radiotherapy (SBRT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medulla Oblongata OAR Tolerances in SBRT

The medulla oblongata should be treated as spinal cord tissue with a maximum dose constraint of 20 Gy in 3 fractions or 13 Gy in a single fraction to maintain myelopathy risk below 1%, and cumulative dose should not exceed 33 Gy across all treatments. 1, 2

Specific Dose Constraints

The medulla oblongata, as part of the brainstem and continuous with the spinal cord, follows spinal cord dose constraints in SBRT planning:

  • Single fraction SBRT: Maximum point dose ≤13 Gy 2
  • 3-fraction SBRT: Maximum point dose ≤20 Gy 2
  • Cumulative lifetime dose: Maximum ≤33 Gy across all treatments 1
  • Risk threshold: These constraints maintain radiation myelopathy risk below 1% 2

Clinical Context for Spine SBRT

When treating spinal metastases near the medulla (cervical spine), the following fractionation schemes achieve approximately 90% local control at 1 year while respecting spinal cord tolerance 1:

  • 16-24 Gy in 1 fraction
  • 24 Gy in 2 fractions
  • 24-27 Gy in 3 fractions
  • 30-35 Gy in 5 fractions

Careful delineation of the spinal cord/medulla and treating to maximal dose limits are critical strategies to reduce both toxicity risk and treatment failure. 3

Where to Find Guidelines

The most authoritative sources for these constraints include:

  • American Society for Radiation Oncology (ASTRO) recommendations for SBRT dose constraints 1
  • International Stereotactic Radiosurgery Society (ISRS) practice guidelines for spine SBRT 3
  • NRG-BR001 protocol dose constraints, which have been validated in prospective trials combining SBRT with immunotherapy 4

Critical Planning Considerations

Use planning organ at risk volumes (PRV) with appropriate margins around the medulla/spinal cord, especially for centrally located tumors. 1 This accounts for setup uncertainty and organ motion during treatment delivery.

The crude risk of radiation myelopathy in spine SBRT when respecting these constraints is approximately 0.2-1.2%, demonstrating that adherence to these dose limits provides excellent safety 3

Common Pitfalls to Avoid

  • Never exceed cumulative spinal cord/medulla dose of 33 Gy across all treatments, including any prior conventional radiotherapy 1
  • Do not use conventional low-dose palliative radiation (8 Gy in 1 fraction) for patients with reasonable life expectancy, as this achieves suboptimal local control and increases risk of subsequent spinal cord compression 1, 2
  • Ensure advanced dose calculation algorithms (type B) are used for treatment planning to accurately account for tissue heterogeneity near the medulla 1

References

Guideline

Dose Constraints in Stereotactic Body Radiation Therapy (SBRT)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Dose Constraints for Organs at Risk in Abdominal SBRT

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.